Rezolute Presents Data on Hyperinsulinism Treatments at ENDO 2026
Event summary
- Rezolute presented four data sets at the 2026 ENDO meeting, including natural history studies and clinical outcomes for ersodetug in congenital and tumor hyperinsulinism (HI).
- Meta-analysis and claims-based studies quantified adverse neurologic and health-economic outcomes in congenital HI.
- Case series of 9 tumor HI patients showed 75% achieved complete discontinuation of IV dextrose/TPN in the Expanded Access Program.
- Oral presentation reviewed previously reported Phase 3 sunRIZE study results for ersodetug in congenital HI.
The big picture
Rezolute's ENDO 2026 presentations underscore the critical unmet need in hyperinsulinism treatment, particularly for refractory cases. The company's focus on both congenital and tumor HI positions it uniquely in the ultra-rare disease space, where therapeutic options remain limited. The strategic value lies in demonstrating ersodetug's potential as a downstream insulin receptor modulator, applicable across multiple HI etiologies.
What we're watching
- Regulatory Pathway
- Whether the natural history data will strengthen ersodetug's regulatory positioning for congenital HI approval.
- Clinical Efficacy
- How the tumor HI case series outcomes compare to existing treatment standards and impact future trial design.
- Market Potential
- The pace at which Rezolute can translate these data points into commercialization strategies for both congenital and tumor HI indications.
Related topics